Hospital
Norton - Kings Daughters Health, INC
Norton - Kings Daughters Health, INC was paid $8.93M by Medicaid between Jan 2018 and Nov 2024, across 115 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoNORTON - KINGS DAUGHTERS HEALTH, INC
MADISON, IN 47250
MADISON, IN 47250
33aNPI1518916048assigned 05/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$8.93M
24GClaims263,330
24DCodes billed115
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#37 of 69
Median peer was paid$9.76M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,216 | $604K | |
| 2019 | 35,136 | $1.08M | |
| 2020 | 33,405 | $1.10M | |
| 2021 | 44,002 | $1.67M | |
| 2022 | 44,664 | $1.48M | |
| 2023 | 37,913 | $1.63M | |
| 2024incomplete | 29,994 | $1.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 23,982 | 19,516 | $2.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 13,641 | 10,402 | $1.52M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 10% | 6,741 | 5,692 | $905K |
| 71045 | Radiologic examination, chest; single view | 6.4% | 6,691 | 5,181 | $569K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.1% | 8,843 | 6,707 | $366K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 3,531 | 727 | $331K |
| 80053 | Comprehensive metabolic panel | 2.1% | 38,230 | 26,314 | $185K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.0% | 3,993 | 3,253 | $178K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 2,605 | 1,885 | $177K |
| 62323 | 1.7% | 294 | 220 | $156K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 436 | 367 | $127K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 6,139 | 4,956 | $124K |
103 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 634 | $109K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 763 | $108K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 315 | $106K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 33,608 | $101K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,505 | $66K |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,440 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,557 | $56K |
| 94760 | <1% | 1,288 | $55K | |
| 99218 | <1% | 269 | $49K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,063 | $46K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 652 | $45K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 808 | $44K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 164 | $41K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 276 | $39K |
| 99217 | <1% | 230 | $38K | |
| 87631 | <1% | 452 | $38K | |
| 97597 | <1% | 460 | $36K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 808 | $30K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 708 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 531 | $30K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 21 | $26K |
| 43235 | <1% | 31 | $25K | |
| 84484 | <1% | 4,358 | $25K | |
| 80061 | Lipid panel | <1% | 3,369 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,558 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,915 | $20K |
| 80050 | General health panel | <1% | 325 | $20K |
| 85027 | <1% | 4,282 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,295 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,711 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 568 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 922 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 429 | $14K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 553 | $14K |
| 36591 | <1% | 234 | $13K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 16 | $12K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 358 | $10K |
| 81001 | <1% | 8,350 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 621 | $10K |
| 71250 | <1% | 74 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 274 | $7K |
| 84439 | <1% | 1,084 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,463 | $5K |
| 97602 | <1% | 88 | $5K | |
| 83690 | <1% | 1,941 | $5K | |
| 82607 | <1% | 509 | $4K | |
| 83735 | <1% | 1,116 | $4K | |
| 83874 | <1% | 651 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 298 | $3K |
| 87420 | <1% | 307 | $3K | |
| 97161 | <1% | 18 | $2K | |
| 81025 | <1% | 785 | $2K | |
| 81003 | <1% | 2,482 | $2K | |
| 45384 | <1% | 28 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 45 | $2K |
| 96367 | <1% | 50 | $1K | |
| 83605 | <1% | 279 | $1K | |
| 87040 | <1% | 375 | $1K | |
| 83880 | <1% | 79 | $1K | |
| 94060 | <1% | 17 | $1K | |
| 88142 | <1% | 75 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $663.24 |
| 85610 | <1% | 427 | $602.50 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,170 | $587.94 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,752 | $411.67 |
| 83655 | <1% | 30 | $406.00 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 55 | $294.58 |
| 94726 | <1% | 62 | $279.04 | |
| 82248 | <1% | 127 | $247.78 | |
| J3490 | Unclassified drugs | <1% | 130 | $238.41 |
| 82805 | <1% | 14 | $187.30 | |
| 82746 | <1% | 28 | $159.27 | |
| 86803 | <1% | 16 | $119.56 | |
| 86703 | <1% | 16 | $114.87 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 688 | $110.90 |
| 87077 | <1% | 27 | $103.33 | |
| 87186 | <1% | 22 | $84.09 | |
| 87340 | <1% | 16 | $59.29 | |
| 86850 | <1% | 13 | $56.51 | |
| 94799 | <1% | 67 | $55.41 | |
| 82550 | <1% | 12 | $52.08 | |
| 82043 | <1% | 52 | $49.40 | |
| 84550 | <1% | 13 | $46.32 | |
| 82570 | <1% | 50 | $37.33 | |
| 82962 | <1% | 59 | $37.22 | |
| 86592 | <1% | 16 | $35.77 | |
| 85730 | <1% | 29 | $30.52 | |
| 94729 | <1% | 34 | $16.90 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,342 | $0.75 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 622 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 180 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,140 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 359 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 584 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 94 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 96 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 41 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 93 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 44 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 30 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 28 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 86 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOZIER, CAROL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Lifestream Behavioral Center INC | Leesburg, FL | $16.10M |
| Norton - Kings Daughters Health INC | Madison, IN | $1.32M |
| Norton - Kings Daughters Health INC | Madison, IN | $664K |
| Lifestream Behavioral Center INC | Leesburg, FL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.